Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketorolac + naproxen is a combination of two nonsteroidal anti-inflammatory drugs (NSAIDs) used for pain management. Ketorolac is indicated for the short-term treatment (up to 5 days) of moderately severe acute pain that would otherwise require opioid analgesics, while naproxen is used to treat mild to moderate pain, inflammation, and fever. Both drugs exert their effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for converting arachidonic acid into prostaglandins—key mediators of inflammation, pain, and fever. By blocking these enzymes, both agents reduce prostaglandin synthesis leading to decreased inflammation and analgesia. Ketorolac is considered more potent than most other NSAIDs but carries a higher risk of gastrointestinal side effects if used long-term[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + naproxen.